Overview

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Status:
Recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.

Phase:

Phase 3

Details

Lead Sponsor:

Meiji Seika Pharma Co., Ltd.

Treatments:

Aztreonam
Cefepime